KRASCENDO

1. 23:21
   ESMO 2026 现场信号

   Divarasib extended median overall survival to 17.7 months vs 12.0 months with sotorasib or adagrasib in the Krascendo 1 trial, with new olomorasib and daraxonrasib data close behin
2. 23:03
   ESMO 2026 现场信号

   📍 Krascendo 1 🫁 #krasg12c #nsclc #esmo2026 #presidentialSymposium2
3. 22:00
   ESMO 2026 现场信号

   Original Article: Divarasib as Compared with Sotorasib or Adagrasib in 𝘒𝘙𝘈𝘚 G12C–Mutated NSCLC (phase 3 Krascendo 1 trial) https://nej.md/4BiCvbk
4. 20:40
   ESMO 2026 现场信号

   🔬 #ESMO26 | El Dr. @javierDcastro , presidente de @_SEOM, analiza KRASCENDO 1 (LBA5), presentado en la Sesión Presidencial del Congreso @myESMO 2026.
5. 20:40
   中文产业新闻精选

   罗氏 divarasib 在 Krascendo 1 Ⅲ期研究中降低 KRAS G12C 突变晚期非小细胞肺癌死亡风险44%

   罗氏公布 divarasib 的 Krascendo 1 Ⅲ期结果，死亡风险较现有 KRAS G12C 靶向药降低44%。

6. 14:47
   ESMO 2026 现场信号

   הנתונים החדשים מ־ #ESMO26 #ESMO2026
7. 10:35
   ESMO 2026 现场信号

   Krascendo 1 #ESMO26: divarasib vs sotorasib/adagrasib, pretreated KRAS G12C NSCLC
8. 06:33
   ESMO 2026 现场信号

   🚨 #ESMO26 | Phase III KRAScendo 1 demonstrates a major advance in previously treated KRAS G12C-mutant NSCLC.
9. 05:28
   ESMO 2026 现场信号

   KRAScendo 1: divarasib met its primary PFS endpoint and improved OS vs a sotorasib-dominant control.
10. 04:03
    ESMO 2026 现场信号

    📣 Presidential Symposium Spotlight 📣: Head-to-head vs sotorasib or adagrasib, divarasib improved PFS (9.8 vs 5.7 mo; HR, 0.58) and OS (HR, 0.56) in previously treated KRAS G12C–mut
11. 03:37
    ESMO 2026 现场信号

    ESMO 2026 Presidential Symposium II recap: survival benefits reported across phase 3 Krascendo 1, SAFFRON, CLARITY-Gastric01, and HARMONi-GI1 trials in lung and gastrointestinal ca
12. 01:09
    ESMO 2026 现场信号

    🚨 Major KRAS G12C NSCLC results at #ESMO26!
13. 00:01
    ESMO 2026 现场信号

    KRAScendo 1: the first head-to-head comparison in KRAS G12C-targeted therapy, presented at ESMO and published in NEJM.
14. 00:00
    ESMO 2026 现场信号

    Brilliant discussion from Dr. @BenjaminBesseMD at #ESMO26 on the Krascendo 1 study of divarasib vs sotorasib/adagrasib. Rightly points out lack of crossover in a study with a PFS e

1. 23:58
   ESMO 2026 现场信号

   🫁 #ESMO26 Krascendo 1 (ph III): divarasib beats soto/ada head-to-head in 2L+ KRAS G12C NSCLC
2. 23:54
   ESMO 2026 现场信号

   ✨ PRACTICE CHANGING ✨ data from #ESMO26
3. 23:50
   ESMO 2026 现场信号

   KRaSCENDO Trial. Excellent results comparing Divarasib (anext generation KRAS inhibitor) with sotorasib showing a clear benefit in PFS, OS, with rapid and durable responses. @on
4. 23:49
   ESMO 2026 现场信号

   Dr. Ferdinandos Skoulidis of UT MD Anderson presents late-breaking results from the Phase 3 KRAScendo 1 trial in the Presidential Symposium at #ESMO26. The findings offer new insig
5. 23:48
   ESMO 2026 现场信号

   Practice-changing KRAS G12C data! @Fskoulidis presents Krascendo 1 Ph.III: divarasib vs sotorasib/adagrasib in pretreated NSCLC. PFS 9.8 vs 5.7 mo (HR 0.58; p<0.0001). OS 17.7 v
6. 23:47
   ESMO 2026 现场信号

   Divarasib is improving the existing data in PFS , OS and ORR in KRAS G12C NSCLC in the Krascendo 1 trial. A really good news for our patients!
7. 23:47
   ESMO 2026 现场信号

   🚨 #ESMO26 | Krascendo 1 (Phase 3)
🥇 First head-to-head KRAS G12C inhibitor trial
🥇 First KRAS G12C inhibitor to improve OS in NSCLC
8. 23:46
   ESMO 2026 现场信号

   KRASCENDO trial: Divarasib a second generation KRAS G12C inhibitor improves PFS and OS in mNSCLC compared to 1st Generation sotorasib. #ESMO2026
9. 23:43
   ESMO 2026 现场信号

   It's time!! The second Presidential Symposium is officially underway. Check back tonight for live coverage of Krascendo 1, SAFFRON, CLARITY-Gastric 01, and HARMONi-GI1 @myESMO #ESM
10. 23:42
    ESMO 2026 现场信号

    KRASCENDO 1: diva v soto/adag; off inhibitor; pretreated; n338: PFS HR 0.58; 4.1m longer mPFS; OS HR 0.56; 5.7m longer OS; mDOR 11.9m ORR 58%; CNS activity not as deep; #ESMO26 @BT
11. 23:42
    ESMO 2026 现场信号

    After expertly delivered #ESMO26 plenary, phase III Krascendo 1 study from Dr. @FSkoulidis now @NEJM. Divarasib superior with PFS 9.8m vs 5.7m (HR 0.58) and OS 17.7m vs 12m (HR 0.5
12. 23:38
    ESMO 2026 现场信号

    🔥Krascendo 1: Divarasib vs sotorasib/adagrasib in previously treated KRAS G12C-mutated NSCLC
13. 23:35
    ESMO 2026 现场信号

    #ESMO26: The potent KRAS G12C inhibitor divarasib outperforms sotorasib and adagrasib in advanced KRAS G12C-mutated non-small cell lung cancer (#NSCLC) in the phase III Krascendo 1
14. 23:35
    ESMO 2026 现场信号

    Presented at #ESMO26:
15. 23:15
    ESMO 2026 现场信号

    Proud to contribute to the Phase III Krascendo 1 study, presented at #ESMO2026 and published in @NEJM. Co-author @BoWangMD1 called the findings “potentially practice-changing” for
16. 21:00
    ESMO 2026 现场信号

    🫁 Coming up at #ESMO26: The second Presidential Symposium kicks off at 4:30 CET with the presentation of Krascendo 1 by @FSkoulidis of @UTMDAnderson!
17. 20:15
    ESMO 2026 现场信号

    #ESMO26 Day 3: Midday Updates
18. 19:20
    ESMO 2026 现场信号

    4 studies I’m watching today at #ESMO26
19. 15:31
    ESMO 2026 现场信号

    Day 3 of #ESMO26 is about to begin!

1. 10:15
   ESMO 2026 现场信号

   1/ My top 7 thoracic picks for #ESMO26 (Madrid, Oct 23–27), ranked. @myESMO

1. 02:04
   ESMO 2026 现场信号

   One of my most anticipated #ESMO26 presentations: Krascendo 1 (LBA5) — phase III divarasib vs sotorasib/adagrasib in previously treated KRAS G12C+ NSCLC. Roche reports positive P…

当前热度 172·可比范围峰值 181（10月26日 07:00）·近 24 小时可比范围变化 +19%·当前参与者 29

上图是参与者计数，下图是热度。趋势仅比较持续完整观测到的相同主体，范围可能小于当前热度统计。移动指针或点击图表查看每小时读数；键盘可用左右方向键切换。